PRKCB and rheumatoid arthritis: We identified nine novel risk proteins (RELA, ETS1, NFATC1, BATF, LCK, PIK3R1, PRKCB, RASGRP1,and FYN) as potential therapeutic targets for RA and they significantly contribute in the disease pathogenesis.